Clinical Trials in Miami

Showing 6781-6800 of 11,431 trials

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

NCT02760615

The purpose of this study is to evaluate in a step-wise approach the disease drug-drug interaction (DDI) potential for vedolizumab to indirectly affect the exposure of cytochrome P-450 (CYP) substrate drugs by modulating pro-inflammatory cytokines in participants with ulcerative colitis (UC) or Crohn's disease (CD) who are treated with vedolizumab.

Colitis, UlcerativeCrohn Disease

TakedaStarted Nov 2016

Cypress, California, United States • Miami, Florida, United States

UNKNOWNNA< 1 mile

Sebacia Postmarket Study of Real-World Use

NCT03818555

Postmarket study of Sebacia Microparticles treatment during adoption into clinical use for patients with mild to moderate inflammatory acne vulgaris.

Acne Vulgaris

Sebacia, Inc.125 participantsStarted Jan 2019

Miami, Florida, United States • Boston, Massachusetts, United States • Murfreesboro, Tennessee, United States +3 more locations

TERMINATEDPhase 2< 1 mile

Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)

NCT02418754

The primary objective of the study was to explore the effect of REGN2176-3 on the Early Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (AMD), compared to intravitreal aflibercept injection (IAI) monotherapy. The secondary objectives of the study were the following: * To explore the effect of 2 dose levels of IVT REGN2176-3 on anatomical changes of CNV in participants with nAMD compared to IAI monotherapy (at week 12) * To evaluate if short-term treatment with REGN2176-3 followed by IAI monotherapy offered the same or additional benefit compared to continuous treatment with REGN2176-3. Also to determine if there was benefit in initiating IAI treatment prior to REGN2176-3 compared to continuous treatment with IAI. * To assess the safety and tolerability of IVT REGN2176-3 in participants with nAMD

Neovascular Age-Related Macular Degeneration

Regeneron Pharmaceuticals505 participantsStarted May 2015

Phoenix, Arizona, United States • Tucson, Arizona, United States • Arcadia, California, United States +81 more locations

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

Sebacia Postmarket Study of Real-World Use

Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)

Find Trials by Condition in Miami

Study to Assess the Relationship Between Daily Dosing of NRPT and Changes in Liver Fat in Healthy Volunteers

A Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies

Exploratory Study of Relationships Between Malodor and Urine Metabolomics

Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

Evaluation of Memory Skills in Patients Receiving Radiation Therapy for Brain Metastases

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas

Radiation Therapy Plus Chemotherapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum

The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.

Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer

Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label

The Dystonia Coalition Natural History and Biospecimen Repository for Isolated Dystonias

Topical Rapamycin to Erase Angiofibromas in TSC